Hypogonadism is a condition caused by the deficiency of the male sex hormone, testosterone, and a new study in Lancet Health Longevity looks at the short- to medium-term safety of testosterone treatment.
About:
Analysis of data from more than 3,400 patients with hypogonadism from 17 clinical trials found little evidence that testosterone treatment increases the risk of cardiovascular events such as arrhythmia, heart attack, and stroke, in the short to medium terms.
Testosterone replacement therapy is the standard treatment for hypogonadism, which can cause sexual dysfunction, weakening of bones and muscles, and reduced quality of life. Risk factors include ageing (as testosterone levels decline with age), obesity and diabetes.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
